Targeting a specific RNA to treat aggressive prostate cancer
Therapeutic Targeting of The Long Noncoding RNA SCHLAP1 in Aggressive Prostate Cancer
This study is looking at a specific RNA called SChLAP1 that is connected to tougher types of prostate cancer, and it's for anyone affected by this disease, as researchers want to find out how SChLAP1 makes the cancer harder to treat and spread, so they can come up with better ways to help patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10763875 on NIH RePORTER |
What this research studies
This research focuses on a long noncoding RNA called SChLAP1, which is linked to aggressive forms of prostate cancer. The study aims to understand how SChLAP1 contributes to therapy resistance and cancer spread, which are major challenges in treating prostate cancer. By investigating the molecular mechanisms of SChLAP1, researchers hope to develop new therapeutic strategies that can effectively target this RNA and improve patient outcomes. The approach includes analyzing the interactions of SChLAP1 with other cellular components to identify potential treatment pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with aggressive or metastatic prostate cancer who have not responded to standard therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not developed therapy resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for patients with therapy-resistant prostate cancer, potentially improving survival rates.
How similar studies have performed: While targeting long noncoding RNAs is a relatively novel approach, preliminary studies have shown promise in similar contexts, indicating potential for success.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Hargrove, Amanda E — Duke University
- Study coordinator: Hargrove, Amanda E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.